Cardiovascular risk reduction in type 2 diabetes: What the non‐specialist needs to know about current guidelines

Documenti analoghi

• Increased risk of type 1 diabetes in patients with autoimmune conditions—Further nuance needed
  di: Yafei Liu, et al.
  Pubblicazione: (2025)
• Effect of tirzepatide on the risk of diabetic retinopathy in type 2 diabetes
  di: Djordje S. Popovic, et al.
  Pubblicazione: (2024)
• An overview of insulin therapy for the non‐specialist
  di: Philip D. Home
  Pubblicazione: (2025)
• Cardiovascular risk reduction with glucagon‐like peptide‐1 receptor agonists is proportional to HbA1c lowering in type 2 diabetes: An updated meta‐regression analysis incorporating FLOW and SOUL trials
  di: Masashi Hasebe, et al.
  Pubblicazione: (2025)
• Fracture risk revisited: Bone mineral density T‐score and fracture risk in type 2 diabetes
  di: V. Van Hulten, et al.
  Pubblicazione: (2024)